Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544445 | 0.87 | HTT (0.57) | HTTMEN1KMT2ATAAR1LMNA | |
| SCHEMBL27621739 | 0.85 | OPRK1 (0.55) | OPRK1OPRM1OPRD1HTTMEN1 | |
| SCHEMBL12362988 | 0.84 | OPRK1 (0.64) | OPRK1OPRM1OPRD1HTTMEN1 | |
| SCHEMBL12128568 | 0.83 | TAAR1 (0.58) | OPRK1OPRM1OPRD1TAAR1TSHR | |
| SCHEMBL79747 | 0.80 | HTT (0.62) | OPRK1OPRM1OPRD1HTTMEN1 | |
| SCHEMBL12772088 | 0.78 | MEN1 (0.53) | OPRM1HTTMEN1KMT2ATAAR1 | |
| SCHEMBL9320386 | 0.78 | HTT (0.66) | OPRK1OPRM1OPRD1HTTMEN1 | |
| Water SCHEMBL28303092 | 0.78 | HTT (0.61) | OPRK1OPRM1OPRD1HTTMEN1 | |
| Bromide SCHEMBL15391224 | 0.78 | HTT (0.61) | OPRK1OPRM1OPRD1HTTMEN1 | |
| Hydrochloric Acid SCHEMBL2313460 | 0.78 | HTT (0.61) | OPRK1OPRM1OPRD1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090589-B2 | Specific nNOS inhibitors for the therapy and prevention of human melanoma | NORTHWESTERN UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090589-B2 | Specific nNOS inhibitors for the therapy and prevention of human melanoma | NORTHWESTERN UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-29 | — | — | US | disclosed |
| US-8642282-B2 | Inhibitors of nitric oxide synthase for treatment of melanoma | NORTHWESTERN UNIVERSITY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642282-B2 | Inhibitors of nitric oxide synthase for treatment of melanoma | NORTHWESTERN UNIVERSITY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120238016-A1 | Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma | NORTHWESTERN UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| US-20120238016-A1 | Specific nNOS Inhibitors for the Therapy And Prevention Of Human Melanoma | NORTHWESTERN UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| WO-2012097121-A2 | SPECIFIC NNOS INHIBITORS FOR THE THERAPY AND PREVENTION OF HUMAN MELANOMA | NORTHWESTERN UNIVERSITY (US) | 2012-07-19 | — | — | WO | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080176907-A1 | NOS Inhibitors For Treatment Of Motor Deficit Disorders | NORTHWESTERN UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176907-A1 | NOS Inhibitors For Treatment Of Motor Deficit Disorders | NOS1, NOS3, SMN1; SMN2 | OPRK1 1456/4885OPRM1 1631/4885OPRD1 894/4885 |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | OPRK1 642/4885OPRM1 353/4885OPRD1 802/4885 |
| US-20140147920-A1 | Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma | NOS3, NOS1, NOS2 | OPRK1 2265/4885OPRM1 2656/4885OPRD1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.